Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ET
Company Participants
Christine Cassiano - Chief Communications Officer
Dr. David Chang - President and CEO
Dr. Zachary Roberts - Executive Vice President, Research and Development and CMO
Dr. Eric Schmidt - Chief Financial Officer
Conference Call Participants
Tyler Van Buren - TD Cowen
Matt Borsch - Goldman Sachs
Michael Yee - Jefferies
Mark Breidenbach - OpCo
Jack Allen - Baird
Brian Cheng - JPMorgan
John Newman - Canaccord Genuity
Kalpit Patel - B. Riley
Asthika Goonewardene - Truist
Reni Benjamin - JMP Securities
Jason Gerberry - Bank of America Securities
William Pickering - Bernstein
Luca Issi - RBC Capital
Sami Corwin - William Blair
Ben Burnett - Stifel
Operator
Hello and thank you for standing by. And welcome to the Allogene Therapeutics First Quarter 2020 Conference Call. After the speaker’s presentation, there will be a question-and-answer session. [Operator Instructions]
Please be aware that today’s conference call is being recorded. I would now like to turn the call over to Christine Cassiano, Chief Communications Officer. Ms. Cassiano, please go ahead.
Christine Cassiano
Thank you, Operator, and welcome to our call. Today, after market closed, Allogene issued a press release that provides a business update and financial results for the first quarter of 2023. This press release and today’s webcast are both available on our website. Following our prepared remarks, we will host a Q&A session. We ask you to limit your questions to one per person as we will keep this call to an hour and do our best to get in as many as possible.
Joining me today are Dr. David Chang, President and Chief Executive Officer; Dr. Zachary Roberts, Executive Vice President of Research and Development and Chief Medical Officer; and Dr. Eric Schmidt, Chief Financial Officer.
During today’s call we will be making forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities and 2023 financial guidance, among certain things.
These forward-looking statements are based on current information, assumptions and expectations that are subject to change. A description of potential risks can be found in our earnings press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements and Allogene disclaims any obligation to update these statements.